Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial

Robert Seifert1,2,3,4,5, David Kersting1,3,4, Christoph Rischpler1,3,4, Patrick Sandach1,3,4, Justin Ferdinandus1,3,4,5, Wolfgang P. Fendler1,3,4, Kambiz Rahbar2, Matthias Weckesser2, Lale Umutlu3,4,6, Christine Hanoun3,4,7, Andreas Hüttmann1,3,4,7, Hans Christian Reinhardt3,4,7, Bastian von Tresckow1,3,4,7, Ken Hermann1,3,4, Ulrich Dührsen1,3,4,7,8 and Michael Schäfers2,8

The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-based treatment intensification over continued standard therapy with CHOP (plus rituximab (R)) in CD20-positive lymphomas. We hypothesized that PET analysis of all lymphoma manifestations may identify patients who benefitted from treatment intensification. A previously developed neural network was employed for iPET analysis to identify the highest pathological FDG uptake (max-SUVmax) and the mean FDG uptake of all lymphoma manifestations (mean-SUVmean). High mean-SUVmean uptake was determined separately for iPET-positive and iPET-negative patients. The endpoint was time-to-progression (TTP). There was a significant interaction of additional rituximab and mean-SUVmean in the iPET-negative group (HR = 0.6, p < 0.05). Patients with high mean-SUVmean had significantly prolonged TTP when treated with 6xR-CHOP + 2 R (not reached versus 52 months, p < 0.05), whereas max-SUVmanual failed to show an impact of additional rituximab. In the iPET-positive group, patients with high mean-SUVmean had a significantly longer TTP with R-CHOP than with the Burkitt protocol (14 versus 4 months, p < 0.01). Comprehensive iPET evaluation may provide new prognosticators in aggressive lymphoma. Additional application of rituximab was associated with prolonged TTP in iPET-negative patients with high mean-SUVmean. Comprehensive iPET interpretation could identify high-risk patients who benefit from study-specific interventions.

Leukemia (2022) 36:2845–2852; https://doi.org/10.1038/s41375-022-01713-y

INTRODUCTION

Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed after 1–4 cycles of chemotherapy (interim PET, iPET) predicts the outcome in aggressive non-Hodgkin lymphoma [1]. In several trials, iPET was employed to identify patients who might benefit from study-specific treatment changes [2, 3]. The ‘Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas’ (PETAL) trial investigated, if treatment intensification can prolong event-free survival (EFS) in patients with a positive (i.e., no sufficient response to previous therapy) iPET result [3]. Treatment intensification in patients with a negative (i.e., response to previous therapy) interim scan was also studied. The study outcome was negative, none of the protocol-mandated treatment changes could improve the outcome. One interpretation of the disappointing result is that the method used to define a positive versus a negative iPET scan may have been inadequate [3].

In clinical routine and in the PETAL study, the assessment of iPET exclusively depends on the lymphoma manifestation with the most intense FDG uptake, which is the basis of the Deauville and delta-SUVmax methods [4–6]. Recent studies indicate that more comprehensive FDG-PET/CT analyses taking into account all manifestations of a malignant disease are also feasible [7–9]. However, these analyses are time-consuming, precluding their use in clinical routine. Yet, preliminary data suggest that a neural network based software may assist in the segmentation of lymphoma manifestations [10, 11]. We, therefore, hypothesized that comprehensive FDG-PET analysis is feasible and could be superior to manual single lesion evaluation.

The aim of the present study was twofold. First, using PET data of the PETAL trial, we investigated, if the mean FDG uptake of all lymphoma manifestations prognosticates time-to-progression (TTP). Second, we investigated, if the comprehensive iPET analysis identifies patient subgroups who benefitted from treatment intensification.
METHODS

Patients

Of all patients enrolled in the PETAL trial \( (n = 862) \), only those with FDG-PET/CT scans available for post-hoc analyses were included in the present study. Additionally, patients scanned at the Department of Nuclear Medicine Münster were excluded from the analysis. This was necessary, as the neural network assisted software used for PET analysis was developed and trained solely with FDG-PET/CT data from Münster, as previously published [12]. Patients gave informed consent for study enrollment. Figure 1 depicts the patients’ flow-chart. Patient characteristics are shown in Table 1. The primary endpoint was TTP defined as time from interim PET until disease progression. The endpoint was defined before reanalysis start and was used to minimize effects of treatment related toxicity or other morbidities.

Randomization

Randomization was based on the iPET evaluation using the delta-SUV\(_{\text{max}}\) method. Patients with a decline of FDG uptake >66% in the most FDG-avid lesion compared to the baseline scan were regarded to have a negative

---

**Table 1.** Patient characteristics.

| Patient characteristics | R-CHOP vs. R-CHOP +2 R | (R-)CHOP vs. Burkitt protocol* | CHOP* | Total cohort |
|-------------------------|------------------------|--------------------------------|-------|-------------|
| \( n \)                | 397                    | 59                             | 27    | 483         |
| Age [years]             | 58 (14.2)              | 59.1 (13.4)                    | 49.5 (18.1) | 57.8 (14.5) |
| Histological subtype    |                        |                                |       |             |
| DLBCL                   | 312 (78.6%)            | 35 (59.3%)                     | 1 (3.7%) | 348 (72.0%) |
| Other large B-cell      | 38 (9.6%)              | 9 (15.3%)                      | 1 (3.7%) | 48 (9.9%)   |
| Lymphoma                |                        |                                |       |             |
| Follicular lymphoma     | 21 (5.3%)              | 4 (6.8%)                       | 0 (0%) | 25 (5.2%)   |
| T-cell lymphoma         | 2 (0.5%)               | 10 (16.9%)                     | 25 (96.2%) | 37 (7.7%) |
| IPI risk group          |                        |                                |       |             |
| Low                     | 158 (39.8%)            | 14 (23.7%)                     | 13 (48.1%) | 185 (38.3%) |
| Low-intermediate        | 103 (25.9%)            | 16 (27.1%)                     | 6 (22.2%) | 125 (25.9%) |
| High-intermediate       | 85 (21.4%)             | 16 (27.1%)                     | 4 (14.8%) | 105 (21.7%) |
| High                    | 51 (12.8%)             | 13 (22.0%)                     | 4 (14.8%) | 68 (14.1%) |
| IPI parameters          |                        |                                |       |             |
| Age > 60                | 202 (50.9%)            | 33 (55.9%)                     | 18 (66.7%) | 244 (50.5%) |
| Stage II or IV          | 223 (56.2%)            | 44 (74.6%)                     | 17 (63.0%) | 284 (58.8%) |
| Elevated LDH            | 218 (54.9%)            | 40 (67.8%)                     | 11 (40.7%) | 269 (55.7%) |
| ECOG > 1                | 35 (8.8%)              | 9 (15.3%)                      | 3 (11.1%) | 47 (9.7%)   |
| Extranodal site >1      | 109 (27.5%)            | 19 (32.2%)                     | 7 (25.9%) | 135 (28.0%) |
| Interim Deauville score >2 | 279 (70.3%)        | 55 (93.2%)                     | 20 (74.1%) | 354 (73.3%) |

Standard deviation is shown in parentheses.

CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, DLBCL diffuse large B-cell lymphoma, ECOG Eastern Cooperative Oncology Group performance status, IPI International Prognostic Index, LDH lactate dehydrogenase, R rituximab.

*Interim PET-positive patients with CD20-negative lymphomas received CHOP or CHOP followed by the Burkitt protocol without rituximab. Interim PET-negative patients with CD20-negative lymphomas received CHOP without rituximab.
interim PET scan; patients with a lesser decline, an increase, or new lesions were considered to have a positive scan (Fig. 2).

Patients with CD20-positive lymphomas and a negative interim PET scan were (pseudo-)randomized to receive a total of 6 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; 2 cycles before and 4 cycles after iPET scanning) or 6xR-CHOP plus 2 additional applications of rituximab. As detailed in a previous secondary analysis of the PETAL trial, pseudo-randomization was due to the fact that all patients treated with 6xR-CHOP or 6xR-CHOP + 2 R were included, and not only those specifically randomized between these options [13]. Before the trial period of randomization, all iPET-negative patients with CD20-positive lymphomas received 6xR-CHOP, and after the conclusion of randomization, all such patients received 6xR-CHOP + 2 R.

Patients with a positive iPET scan were randomized to receive a total of 8 cycles of (R-)CHOP or 2 cycles of (R-)CHOP followed by 6 blocks of an intensive Burkitt’s lymphoma protocol. Rituximab was restricted to patients with CD20-positive lymphomas.

Image analysis

The manual image analysis of the PETAL trial was used for comparison. For re-analysis, the neural network-based PET-assisted reporting system software prototype (PARS) was employed (Siemens Healthineers, Knoxville, TN, USA). The tool is distributed by Siemens upon request. The AUC of this software prototype (PARS) was employed (Siemens Healthineers, Knoxville, TN, USA). The tool is distributed by Siemens upon request. The AUC of this software prototype (PARS) was employed (Siemens Healthineers, Knoxville, TN, USA). The tool is distributed by Siemens upon request. The AUC of this software prototype (PARS) was employed (Siemens Healthineers, Knoxville, TN, USA).

Image metrics

In the original PETAL publication, the SUV_{max} of the single most FDG-avid lesion was used to assess the overall metabolic activity of the lymphoma [3]. This manually determined interim FDG-PET value is designated max-SUV_{manual} in this study.

Using the PARS neural network (AI), the lymphoma lesion with the highest FDG avidity was measured and designated max-SUV_{AI}. Additionally, PARS automatically segmented all lymphoma manifestations in the acquired PET images. We argued that averaging the FDG uptake of each lesion may lead to an improved assessment of the disease severity compared to the uptake of only the hottest lesion. Therefore, the metric mean-SUV_{AI} was introduced, which denotes the average SUV of all segmented lesions. The three metrics (max-SUV_{manual}, max-SUV_{AI}, mean-SUV_{AI}) were tested as PET-derived prognosticators.

Statistical analysis

The R language and environment were used for Pearson correlation, log-rank test, uni- and multivariable Cox regression analysis and descriptive statistics [14]. The STARD and TRIPOD guidelines were followed. For the interaction analysis in Cox regression, the treatment was coded as a dummy variable with the range [0–1], the intensified treatment (6xR-CHOP + 2 R or the Burkitt protocol, respectively) being coded as 1. To determine high and low PET uptake, the log-rank statistic of the treatment difference between standard and intensified arm was maximized; this was done separately for the group of patients with a positive or a negative iPET.

PET-derived parameters were log-transformed due to skewed distributions prior to Cox regression analysis. Mean liver uptake was added before the analysis. The H0 hypotheses (treatment intensification does not prolong TTP) were rejected if the p value was <0.05.

RESULTS

Patient characteristics

A total of 483 patients were included in this secondary analysis of the PETAL study of whom 397 were (pseudo-)randomized to 6xR-CHOP versus 6xR-CHOP + 2 R. A positive iPET was observed in 59 patients who were randomized to receive either 8x(R)-CHOP or 2x(R)-CHOP followed by the Burkitt protocol. Detailed patient characteristics are shown in Table 1 and Supplementary Table 1. Figure 3 shows TTP of the cohort dichotomized by the Deauville scale, the mean-SUV_{AI} or the max-SUV_{AI}.

Prognostication of TTP in the total cohort

Max-SUV_{manual} was a statistically significant prognosticator of TTP in univariable Cox regression analysis (hazard ratio [HR] 4.109, 95% CI: 2.922–5.780, p < 0.001). The same was true for max-SUV_{AI} (HR 1.334, 95% CI: 1.185–1.501, p < 0.001) and mean-SUV_{AI} (HR 1.430, 95% CI: 1.224–1.670, p < 0.001). Multivariable Cox regression analysis of
mean-SUV$_{\text{AI}}$ adjusted for the parameters of the International Prognostic Index (IPI) is shown in Supplementary Table 2 (HR 1.572, 95% CI: 1.294–1.909, p < 0.001).

**Effect of therapy intensification in the randomized cohorts**

In the interim PET-negative group, there was no statistically significant difference in TTP between patients treated with 6xR-CHOP or 6xR-CHOP + 2 R (medians not reached; HR 0.872, 95% CI: 0.590–1.288, p > 0.05; Fig. 4A). Likewise, in the interim PET-positive group, there was no statistically significant difference in TTP between patients treated with 8x(R)-CHOP or 2x(R)-CHOP followed by the Burkitt protocol (7 versus 22 months; HR 1.798, 95% CI: 0.940–3.441, p > 0.05, Fig. 5A).

**Identification of patients in the iPET-negative subgroup who benefitted from treatment intensification by additional rituximab**

All patients referred to 6xR-CHOP or 6xR-CHOP + 2 R were considered in this analysis. To investigate a potential interaction of treatment regime (coded: 6xR-CHOP[0]; 6xR-CHOP + 2 R[1]) and interim PET parameter (as a continuous variable), interaction terms were evaluated in multivariable Cox regressions. A significant interaction term would indicate that patients with higher uptake benefit from intensified treatment. The interaction term (treatment regime × max-SUV$_{\text{manual}}$) was not a statistically significant prognosticator of TTP (HR 1.339, 95% CI: 0.334–5.371, p > 0.05) in an analysis including treatment regime (6xR-CHOP or 6xR-CHOP + 2 R), max-SUV$_{\text{manual}}$, and the IPI score. The same was true for the interaction term employing max-SUV$_{\text{AI}}$ (HR 0.745, 95% CI: 0.532–1.045, p > 0.05). In contrast, an interaction term employing mean-SUV$_{\text{AI}}$ (treatment regime × mean-SUV$_{\text{AI}}$) was a statistically significant prognosticator of TTP (HR 0.579, 95% CI: 0.340–0.987, p < 0.05) (Supplementary Table 3).

The optimal mean-SUV$_{\text{AI}}$ threshold for patient stratification (SUV 4.89) in the interim PET-negative subgroup was used to group patients into high versus low PET uptake (Fig. 4). In patients with high mean-SUV$_{\text{AI}}$, those treated with 6xR-CHOP + 2 R had significantly longer TTP than those treated with 6xR-CHOP alone (median not reached versus 52 months; HR 0.316, 95% CI: 0.114–0.875, p < 0.05). This was not true for the conventional metrics max-SUV$_{\text{manual}}$ or the decrease in SUV$_{\text{max}}$ between baseline and interim PET (Fig. 4); no subgroup who benefitted from treatment intervention could be identified with these metrics. In the low mean-SUV$_{\text{AI}}$ group, no statistically significant difference was observed between 6xR-CHOP and 6xR-CHOP + 2 R (medians not reached; HR 1.086, 95% CI: 0.702–1.680, p > 0.05).

**Identification of patients in the iPET-positive subgroup who had a disadvantage from treatment intensification by the Burkitt protocol**

The interaction term (treatment regime × mean-SUV$_{\text{AI}}$) was not a statistically significant prognosticator of TTP (HR 0.401, 95% CI: 0.157–1.023, p > 0.05) in a multivariable Cox regression analysis adjusted for treatment regime (8x(R)-CHOP versus 2x(R)-CHOP followed by the Burkitt protocol), mean-SUV$_{\text{AI}}$, and the IPI score (coded: (R-)CHOP[0]; Burkitt protocol[1]; Supplementary Table 4). However, mean-SUV$_{\text{AI}}$ was a statistically significant prognosticator of TTP (HR 2.333, 95% CI: 2.091–4.989, p < 0.05). The optimal mean-SUV$_{\text{AI}}$ threshold (SUV 4.78) for patient stratification in the interim PET-positive subgroup was used to group patients into those with high versus low uptake. All patients who were randomly assigned to 8x(R)-CHOP or 2x(R)-CHOP followed by the Burkitt protocol were evaluated in this analysis. In the high mean-SUV$_{\text{AI}}$ group, patients treated with the Burkitt protocol showed significantly shorter TTP than patients continuing on (R-)CHOP (4 versus 14 months; HR 4.104, 95% CI: 1.455–11.580, p < 0.01; Fig. 5). For comparison, the conventional PET metrics max-SUV$_{\text{manual}}$ and the decrease in SUV$_{\text{max}}$ between baseline and interim PET could also identify subgroups of patients who were disadvantaged from the Burkitt protocol (Fig. 5). In patients with low mean-SUV$_{\text{AI}}$, no statistically significant difference in TTP was observed between the treatment arms (28 versus 30 months; HR 1.909, 95% CI: 0.43–3.293, p > 0.05).

**DISCUSSION**

The interim FDG-PET scans of the treatment intensification PETAL trial were re-analyzed in a comprehensive PET analysis to segment all lymphoma manifestations. The following principal findings arise from this analysis: (1) A fully automated analysis of interim FDG-PET/CTs from lymphoma patients is feasible. (2) The biomarkers derived from the comprehensive PET analysis are statistically significant prognosticators of TTP. (3) The mean-SUV$_{\text{AI}}$ parameter identified patients that benefitted from additional application of rituximab as treatment intensification, which could not be achieved using conventional PET metrics.

(R)-CHOP is the standard first-line treatment for patients with aggressive lymphoma, with cure rates of 60–70%. In patients with (multiply) relapsed disease, several treatment options exist, such as high-dose chemotherapy with autologous hematopoietic stem cell transplantation, allogeneic transplantation, CAR-T cell therapy, immunomodulation, and others [15–17]. Current methods for early prediction of treatment failure, including Deauville-based iPET assessment, appear insufficient.
FDG-PET has a long track record of monitoring initial treatment response to systemic anti-cancer therapy [2, 3, 18]. In principle, early detection of treatment failure could trigger a change in therapy, aiming at improved outcome. However, often only a single target lesion is used to assess treatment failure and guide subsequent therapies. A single lesion, however, cannot accurately capture disease extent and severity. To overcome this limitation, a recent approach tries to employ ctDNA levels as comprehensive biomarker to assess the total lymphoma burden [19]. However, in FDG-PET is comprehensively analyzed, it can also quantify the total lymphoma burden and assess the metabolic heterogeneity of all manifestations. As the delineation of all disease manifestations is too time-consuming for clinical routine, AI-based PET analysis software, like the PARS prototype and others, have been proposed [12, 20].

For the conventional metric max-SUV$_{\text{manual}}$, which takes account of a single lymphoma manifestation, no statistically significant interaction of treatment intensification by additional rituximab was found in the present analysis. In contrast, for the mean-SUV$_{\text{AI}}$ metric, which averages the FDG uptake of all lymphoma manifestations, a statistically significant interaction with treatment intensification was observed. This indicates that the benefit of treatment intensification through additional rituximab is growing with increasing mean-SUV$_{\text{AI}}$. This was corroborated by looking at patients with high mean-SUV$_{\text{AI}}$ who had statistically significantly longer survival when treated with two additional rituximab doses than with 6xR-CHOP alone. Interestingly, patients with high mean-SUV$_{\text{AI}}$ had higher baseline SUV$_{\text{max}}$ compared to patients with low mean-SUV$_{\text{AI}}$ (Supplementary Table 5). This indicates that patients with high mean-SUV$_{\text{AI}}$ might erroneously be read as iPET-negative due to their high baseline SUV$_{\text{max}}$, which could lead to a more pronounced relative reduction, despite metabolically active residual lymphoma at the interim timepoint. The finding is in line with recent studies...
indicating that a more complex PET analysis of lymphoma patients is superior to the IPI index [21].

In patients randomized to 8x(R-)CHOP versus 2x(R-)CHOP followed by the Burkitt protocol, no statistically significant interaction of a PET parameter and treatment intensification was found. However, patients with high mean-SUVAI had statistically significantly longer TTP when they were not treated with the Burkitt protocol. This seems paradoxical as especially patients with very high residual tumor activity seemed to have a disadvantage from therapy intensification. Also, conventional PET metrics such as highest uptake or change in highest uptake between baseline and interim could identify patients who showed longer TTP in response to treatment with R-CHOP over the Burkitt protocol.

CONCLUSION
A comprehensive analysis of interim FDG-PET in patients with aggressive non-Hodgkin lymphoma is feasible. In the PETAL trial, not pre-planned, which might cause an observational bias. Additionally, all patients receiving 6xR-CHOP and 6xR-CHOP + 2 R were included, but only a subfraction was truly randomized (178 of 397 patients). However, non-randomized patients receiving 6xR-CHOP or 6xR-CHOP + 2 R were recruited using the same inclusion criteria in the beginning and at the end of the study period, respectively, which should minimize potential biases. Finally, our primary endpoint was TTP which best reflects the impact of therapy on outcome [7–9]. In contrast, the PETAL trial employed event-free survival (EFS), which also included death unrelated to lymphoma and events such as treatment-related toxicity.

Fig. 5 Effect of treatment intensification by the Burkitt protocol in patients with a positive interim PET scan. Overall, patients receiving treatment intensification by the Burkitt protocol did not have a statistically longer TTP than patients receiving standard R-CHOP (A). Patients with a positive interim PET scan were grouped by an optimized mean-SUVAI threshold (SUV 4.78) into those with high versus low FDG uptake (B). In patients with low mean-SUVAI, no statistically significant difference between patients treated with R-CHOP or the Burkitt protocol was observed (C). In contrast, in the high mean-SUVAI subgroup, patients treated with R-CHOP had statistically significantly longer TTP than those treated with the Burkitt protocol (D). For comparison, the conventional metrics max-SUVmanual (E) and decline in SUVmax between baseline and interim PET (F) could also identify patients who showed longer TTP in response to treatment with R-CHOP over the Burkitt protocol.
this novel approach identified patients who benefitted from protocol-mandated treatment intensification. This might indicate the superiority of average FDG avidity over conventional metrics restricted to the metabolically most active lesion. Future studies should evaluate the use of automated image analysis for interim PET assessment to identify patients who may benefit from a change in therapy.

DATA AVAILABILITY
Data supporting the presented findings may be shared upon request. No consent for sharing of image data was given. The PARS prototype software is available through Siemens Healthineers.

REFERENCES
1. Barrington SF, Mikhail NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3049–58.
2. Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374:2419–29.
3. Dührsen U, Müller S, Hertenstein B, Thomissen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024–34.
4. Lin C, Itti E, Haïoun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626–32.
5. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C, Boellaard R, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. Eur J Cancer. 2020;57:jnumed.120.242412.
6. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: The lugano classification. J Clin Oncol. 2014;32:3059–67.
7. Schmitz C, Rekowski J, Müller SP, Hertenstein B, Franzini C, Ganser A, et al. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. Hematol Oncol. 2020;38:244–56.
8. Schmitz C, Rekowski J, Reineke S, Müller SP, Huttmann A, Klapper W, et al. Metabolic tumor volume, cancer cell fraction, and prognosis—the case of T-cell- histioocyte-rich large B-cell lymphoma. Leuk Lymphoma. 2020;61:1372–9.
9. Schmitz C, Huttmann A, Müller SP, Hanoun M, Boellaard R, Brinkmann M, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Prognostic factors and outcome prediction. J Nucl Med. 2019;60:2024–30.
10. Weber M, Kersting D, Umutlu L, Schäfers M, Rischpler C, Fendler WP, et al. Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer. Eur J Nucl Mol Imaging. 2021;48:3141–50.
11. Capobianco N, Meignan M, Cottereau A-S, Vercellino L, Sibille L, Spottswoode B, et al. Deep learning FDG uptake classification, opportunities, and future directions. Front Immunol. 2021;12:681984.

ACKNOWLEDGEMENTS
We are indebted to our patients who contributed to this study. Templates of BioRender.com were used for figure parts.

AUTHOR CONTRIBUTIONS
RS, JF, DK, UD, KH, and MS conceptualized the work, designed the study, revised the manuscript, and oversaw the analysis. PS, RS, and DK curated the data and performed the PET analysis. RS and DK did the statistical analysis and drafted the manuscript. CR, WPF, KR, MW, LU, CH, AH, HCR, and BT were responsible for data interpretation, analysis as well as writing and revising the manuscript.

FUNDING
Open Access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST
DK received a research grant from Pfizer outside of the submitted work. CR received a research grant from Pfizer, reports consultancy for Pfizer and Addacap, and speaker honoraria from Adacap, Aplylam, BtG, GE Healthcare, Pfizer, and Siemens Healthineers, all outside the submitted work. HCR received consulting and lecture fees from Abbvie, AstraZeneca, Vertex, Roche, and Merck. HCR received research funding from Gilead Pharmaceuticals and AstraZeneca. HCR is a co-founder of CDL Therapeutics GmbH. HK received personal fees from Btg, Bayer, Soef Biosciences, SIRTEX, Addacap, Curium, Endocyte, IPSEN, Siemens Healthineers, GE Healthcare, Amgen, Novartis, ymabs, Aktis, Oncology, Pharma15 as well as non-financial support from ABX and grants from BTG. UD chairs data and safety monitoring boards of studies performed by Amgen and CPT Cellex Patient Treatment. WPF reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speakers bureau), Calyx (consultant), Bayer (consultant, speakers bureau), and Parexel (image review) outside of the submitted work. RS has received research support from the Else Kröner-Fresenius-Stiftung and Boehringer Ingelheim Fonds. The University Hospital Münster, Department of Nuclear Medicine received a research grant from Siemens Healthineers, which supported the execution of the study. All other authors declare no conflict of interest with respect to this manuscript.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41375-022-01713-y.

Correspondence and requests for materials should be addressed to Robert Seifert. Reprints and permission information available at https://doi.org/10.1038/s41375-022-01713-y.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
